Identification

Name
Telmisartan
Accession Number
DB00966  (APRD01247)
Type
Small Molecule
Groups
Approved, Investigational
Description

Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.

Structure
Thumb
Synonyms
  • 4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
  • 4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
  • 4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
  • 4'-[(1,7'-Dimethyl-2'-propyl-1H,3'h-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
  • BIBR 277
  • Telmisartan
External IDs
BIBR 277 / BIBR 277 SE / BIBR 277SE / BIBR-277 / C09CA07
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act TelmisartanTablet40 mgOralActavis Pharma Company2012-10-19Not applicableCanada
Act TelmisartanTablet80 mgOralActavis Pharma Company2012-10-19Not applicableCanada
Auro-telmisartanTablet40 mgOralAuro Pharma Inc2016-04-08Not applicableCanada
Auro-telmisartanTablet80 mgOralAuro Pharma Inc2016-04-08Not applicableCanada
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet40 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet20 mgOralBayer Pharma Ag1998-12-16Not applicableEu
KinzalmonoTablet80 mgOralBayer Pharma Ag1998-12-16Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-telmisartanTablet80 mgOralApotex Corporation2014-07-18Not applicableCanada
Apo-telmisartanTablet40 mgOralApotex Corporation2014-07-18Not applicableCanada
TelmisartanTablet80 mg/1OralSolco healthcare U.S., LLC2017-08-20Not applicableUs
TelmisartanTablet80 mg/1OralTorrent Pharmaceuticals Limited2014-07-07Not applicableUs
TelmisartanTablet20 mg/1OralMesource Pharmaceuticals2014-08-27Not applicableUs
TelmisartanTablet40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2016-08-22Not applicableUs
TelmisartanTablet40 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2014-07-07Not applicableUs
TelmisartanTablet20 mg/1OralCadila Pharnmaceuticals2015-02-05Not applicableUs
TelmisartanTablet20 mg/1OralActavis Pharma Company2014-01-08Not applicableUs
TelmisartanTablet20 mg/1OralQualitest2013-03-062017-02-28Us
International/Other Brands
Micardis / Pritor
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ach-telmisartan HctzTelmisartan (80 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccord Healthcare Limited2014-05-27Not applicableCanada
Ach-telmisartan HctzTelmisartan (80 mg) + Hydrochlorothiazide (25 mg)TabletOralAccord Healthcare Limited2014-05-27Not applicableCanada
Act Telmisartan/hctTelmisartan (80 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Pharma Company2012-10-02Not applicableCanada
Act Telmisartan/hctTelmisartan (80 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-10-02Not applicableCanada
Actelsar HctTelmisartan (80 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Group Hf2013-03-13Not applicableEu
Actelsar HctTelmisartan (80 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Group Hf2013-03-13Not applicableEu
Actelsar HctTelmisartan (80 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Group Hf2013-03-13Not applicableEu
Actelsar HctTelmisartan (80 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Group Hf2013-03-13Not applicableEu
Actelsar HctTelmisartan (40 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Group Hf2013-03-13Not applicableEu
Actelsar HctTelmisartan (80 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Group Hf2013-03-13Not applicableEu
Categories
UNII
U5SYW473RQ
CAS number
144701-48-4
Weight
Average: 514.6169
Monoisotopic: 514.236876224
Chemical Formula
C33H30N4O2
InChI Key
RMMXLENWKUUMAY-UHFFFAOYSA-N
InChI
InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
IUPAC Name
2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl}phenyl)benzoic acid
SMILES
CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O

Pharmacology

Indication

Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).

Structured Indications
Pharmacodynamics

Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. It has the highest affinity for the AT1 receptor among commercially available ARBS and has minimal affinity for the AT2 receptor. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects, as PPARγ is a nuclear receptor that regulates specific gene transcription, and whose target genes are involved in the regulation of glucose and lipid metabolism, as well as anti-inflammatory responses. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.

Mechanism of action

Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPARγ, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPARγ activators.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
APeroxisome proliferator-activated receptor gamma
partial agonist
Human
Absorption

Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).

Volume of distribution
  • 500 L
Protein binding

Highly bound to plasma proteins (>99.5%), mainly albumin and a1-acid glycoprotein. Binding is not dose-dependent.

Metabolism

Minimally metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.

Route of elimination

Following either intravenous or oral administration of 14C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).

Half life

Bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.

Clearance
  • >800 mL/min
Toxicity

Intravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Telmisartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Telmisartan.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acemetacin.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Telmisartan.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Telmisartan.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Telmisartan.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Telmisartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Alminoprofen.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Telmisartan.Approved, Withdrawn
AmbrisentanTelmisartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTelmisartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Telmisartan.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Telmisartan.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Telmisartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Telmisartan.Approved, Illicit
AmphetamineAmphetamine may increase the hypotensive activities of Telmisartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Telmisartan.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Telmisartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Telmisartan.Approved
ApremilastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Telmisartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Telmisartan.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Telmisartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Telmisartan.Approved
AvanafilAvanafil may increase the antihypertensive activities of Telmisartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Telmisartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Telmisartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Telmisartan.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Telmisartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Telmisartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine.Approved
BepridilTelmisartan may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Telmisartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Telmisartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Telmisartan.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Telmisartan.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Telmisartan.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Telmisartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Telmisartan.Approved
BQ-123Telmisartan may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Telmisartan.Approved
BretyliumThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Telmisartan.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Telmisartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Telmisartan.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Telmisartan.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Telmisartan.Approved, Investigational
BupranololTelmisartan may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Telmisartan.Experimental
CafedrineTelmisartan may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Telmisartan.Approved
CandesartanTelmisartan may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Telmisartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Telmisartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Telmisartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Telmisartan.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Celecoxib.Approved, Investigational
CeliprololTelmisartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Telmisartan.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Telmisartan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Telmisartan.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Choline magnesium trisalicylate.Approved
CicletanineTelmisartan may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Telmisartan.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Telmisartan.Approved
CiprofloxacinTelmisartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Telmisartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Telmisartan.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Telmisartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin.Approved
CloranololTelmisartan may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Telmisartan.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Telmisartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Telmisartan.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Telmisartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Telmisartan is combined with Curcumin.Investigational
CyclopenthiazideTelmisartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineTelmisartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Telmisartan.Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Telmisartan.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when Telmisartan is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Telmisartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Telmisartan.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Telmisartan.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Delapril.Experimental
DeserpidineTelmisartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Telmisartan.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Telmisartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Telmisartan.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Telmisartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diclofenamide.Approved
diethylnorspermineTelmisartan may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Telmisartan.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Telmisartan.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Telmisartan.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Telmisartan.Investigational
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Telmisartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Telmisartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Telmisartan.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Telmisartan.Approved, Investigational
DrospirenoneTelmisartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam.Approved
DuloxetineTelmisartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Telmisartan is combined with E-6201.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Telmisartan.Approved
EfonidipineTelmisartan may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Telmisartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Telmisartan.Approved
EpanololTelmisartan may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Telmisartan.Approved
EpoprostenolTelmisartan may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Telmisartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Telmisartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Telmisartan.Approved
exisulindThe risk or severity of adverse effects can be increased when Telmisartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Telmisartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Feprazone.Experimental
Ferulic acidTelmisartan may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Telmisartan.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Telmisartan.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan.Approved, Vet Approved
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Telmisartan.Experimental
GuacetisalThe risk or severity of adverse effects can be increased when Telmisartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Telmisartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Telmisartan.Approved
GuanazodineTelmisartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineTelmisartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Guanfacine.Approved, Investigational
GuanoclorTelmisartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTelmisartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTelmisartan may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Telmisartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Telmisartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
HexamethoniumTelmisartan may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Telmisartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Telmisartan.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Telmisartan.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Telmisartan is combined with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Telmisartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Telmisartan.Approved
IndenololTelmisartan may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Telmisartan.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Telmisartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Telmisartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Telmisartan.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Telmisartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Telmisartan.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Telmisartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Telmisartan.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Telmisartan.Approved
LacidipineTelmisartan may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Telmisartan.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Telmisartan.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Telmisartan.Approved, Investigational
LevodopaTelmisartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Telmisartan.Approved, Investigational
LinsidomineTelmisartan may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Telmisartan.Approved
LofexidineTelmisartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Telmisartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lumiracoxib.Approved, Investigational
MacitentanTelmisartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate.Approved
ManidipineTelmisartan may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Telmisartan.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Telmisartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole.Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Telmisartan.Approved
MethohexitalMethohexital may increase the hypotensive activities of Telmisartan.Approved
MethoserpidineTelmisartan may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Telmisartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Telmisartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Telmisartan.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Telmisartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Telmisartan.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Telmisartan.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Telmisartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Telmisartan.Approved, Investigational
MetyrosineTelmisartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilTelmisartan may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Telmisartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Telmisartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Telmisartan.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Telmisartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Telmisartan.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Telmisartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Telmisartan.Approved, Investigational
MuzolimineTelmisartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Telmisartan.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Telmisartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naftifine.Approved
NaftopidilTelmisartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Telmisartan.Approved
NaproxenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Telmisartan.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Telmisartan.Approved
NicorandilNicorandil may increase the hypotensive activities of Telmisartan.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Niflumic Acid.Approved
NiguldipineTelmisartan may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineTelmisartan may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Telmisartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Telmisartan.Approved
NitrendipineTelmisartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Telmisartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Telmisartan.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Telmisartan.Approved
ObinutuzumabTelmisartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Telmisartan.Withdrawn
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Telmisartan.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Telmisartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Orgotein.Vet Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Telmisartan.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.Approved
OxprenololTelmisartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Telmisartan.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Telmisartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Telmisartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Telmisartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
PentoliniumTelmisartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Telmisartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Perindopril.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Telmisartan.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Telmisartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Telmisartan.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Telmisartan.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Telmisartan.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Telmisartan.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Telmisartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Telmisartan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Telmisartan.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Telmisartan.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Telmisartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Telmisartan.Withdrawn
Platelet Activating FactorTelmisartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideTelmisartan may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Telmisartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Telmisartan.Approved
PrimidonePrimidone may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Telmisartan.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Telmisartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Telmisartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Proquazone.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Telmisartan.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Telmisartan.Approved
PTC299The risk or severity of adverse effects can be increased when Telmisartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Telmisartan.Approved
RamiprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Telmisartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Telmisartan.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Telmisartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Telmisartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Telmisartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Telmisartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Telmisartan.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Telmisartan is combined with Riociguat.Approved
RisperidoneTelmisartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabTelmisartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Telmisartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Telmisartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Telmisartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Telmisartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salsalate.Approved
SaprisartanTelmisartan may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Telmisartan.Approved, Investigational, Vet Approved
SelexipagTelmisartan may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Telmisartan is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Telmisartan is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Telmisartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Telmisartan.Approved
SitaxentanTelmisartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Telmisartan.Approved
Sodium phosphateTelmisartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Telmisartan.Approved
SRT501The risk or severity of adverse effects can be increased when Telmisartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Telmisartan.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Telmisartan.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
TalinololTelmisartan may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Telmisartan.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tarenflurbil.Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Teriflunomide.Approved
TerlipressinTelmisartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineTelmisartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Telmisartan.Approved, Investigational, Withdrawn
TheodrenalineTelmisartan may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Telmisartan.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tiaprofenic acid.Approved
TiboloneTelmisartan may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTelmisartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Telmisartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Telmisartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Telmisartan.Approved
TolazolineTolazoline may increase the hypotensive activities of Telmisartan.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Telmisartan.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin.Approved
TolonidineTelmisartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Telmisartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Telmisartan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Telmisartan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Telmisartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Telmisartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Telmisartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Telmisartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Telmisartan.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Telmisartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Telmisartan.Approved
TribenosideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tribenoside.Experimental
TrichlormethiazideTelmisartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Telmisartan.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Telmisartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Telmisartan.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Telmisartan is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Telmisartan.Approved, Investigational
UnoprostoneTelmisartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Telmisartan.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Telmisartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Telmisartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Telmisartan.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Telmisartan.Approved
VincamineTelmisartan may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Telmisartan.Approved, Investigational
VinpocetineTelmisartan may increase the hypotensive activities of Vinpocetine.Investigational
XipamideTelmisartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineTelmisartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Telmisartan.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. Pubmed.

General References
  1. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. [PubMed:11558835]
  2. Smith DH: Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther. 2002 Oct;24(10):1484-501. [PubMed:12462282]
  3. Kumar AS, Ghosh S, Mehta GN: Efficient and improved synthesis of Telmisartan. Beilstein J Org Chem. 2010 Mar 11;6:25. doi: 10.3762/bjoc.6.25. [PubMed:20502601]
  4. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. [PubMed:20448797]
External Links
Human Metabolome Database
HMDB15101
KEGG Drug
D00627
KEGG Compound
C07710
PubChem Compound
65999
PubChem Substance
46505370
ChemSpider
59391
BindingDB
50043280
ChEBI
9434
ChEMBL
CHEMBL1017
Therapeutic Targets Database
DAP000766
PharmGKB
PA451605
IUPHAR
592
Guide to Pharmacology
GtP Drug Page
HET
TLS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Telmisartan
ATC Codes
C09DB04 — Telmisartan and amlodipineC09DA07 — Telmisartan and diureticsC09CA07 — Telmisartan
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
PDB Entries
3vn2
FDA label
Download (47.4 KB)
MSDS
Download (101 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHypertensive1
1CompletedBasic ScienceHypertensive1
1CompletedSupportive CareHealthy Male Volunteers1
1CompletedTreatmentDiseases of the Circulatory System / Hypertension,Essential1
1CompletedTreatmentHealthy Male Volunteers2
1CompletedTreatmentHealthy Volunteers32
1CompletedTreatmentHyperlipidemias / Hypertension,Essential1
1CompletedTreatmentHyperlipidemias / Hypertensive3
1CompletedTreatmentHypertension and Dyslipidemia1
1CompletedTreatmentHypertensive3
1RecruitingNot AvailableAcute HIV Infection / Human Immunodeficiency Virus (HIV) Infections1
1RecruitingPreventionAlzheimer's Disease (AD)1
1TerminatedTreatmentHyperlipidemias / Hypertensive1
2Active Not RecruitingTreatmentAcute HIV Infection / HIV CNS Involvement1
2CompletedBasic ScienceHypertensive1
2CompletedTreatmentBMI >30 kg/m2 / Insulin Resistance1
2CompletedTreatmentEndothelial Dysfunction1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHypertensive4
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentTransplant, Kidney1
2RecruitingTreatmentAlzheimer's Disease (AD) / Hypertensive1
2, 3CompletedPreventionCoronary Artery Disease / Diabetes Mellitus (DM) / Heart Failure, Unspecified1
3Active Not RecruitingTreatmentDyslipidemias / Hypertensive1
3CompletedBasic ScienceHypertensive / Hypertriglyceridemias / Metabolic Syndromes1
3CompletedDiagnosticMetabolic Syndromes1
3CompletedPreventionCardiac Diseases1
3CompletedPreventionHypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentAcquired Kidney Disease / Children / Chronic Renal Failure (CRF) / Congenital Kidney Disease / Hypertensive1
3CompletedTreatmentDiabetic Nephropathies1
3CompletedTreatmentDyslipidemias / Hypertensive1
3CompletedTreatmentHyperlipidemias / Hypertensive1
3CompletedTreatmentHypertension,Essential1
3CompletedTreatmentHypertensive25
3CompletedTreatmentKidney, Polycystic2
3CompletedTreatmentMetabolic Syndromes1
3RecruitingTreatmentDyslipidemia With Hypertension1
3Unknown StatusTreatmentHyperlipidemias / Hypertensive1
4CompletedNot AvailableHypertensive1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedPreventionHypertensive1
4CompletedPreventionNonvalvular Atrial Fibrillation2
4CompletedPreventionStrokes1
4CompletedTreatmentAbdominal Aortic Aneurysms (AAA)1
4CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
4CompletedTreatmentChronic Kidney Disease (CKD) / Proteinuria1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentCoronary Arteriosclerosis / Hypertensive1
4CompletedTreatmentCoronary Artery Disease / Diabetes / Hypertensive1
4CompletedTreatmentDiabetic Nephropathies1
4CompletedTreatmentDiabetic Nephropathies / Hypertensive2
4CompletedTreatmentEnd-Stage Renal Disease (ESRD) / Inflammatory Reaction1
4CompletedTreatmentEssential Hypertension Complicated by Type 2 Diabetes Mellitus1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHypertensive17
4CompletedTreatmentHypertensive / Impaired Glucose Tolerance (IGT)1
4CompletedTreatmentHypertensive / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Other and unspecified effects of high altitude1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentMetabolic Syndromes1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4Not Yet RecruitingTreatmentDyslipidemias / Hypertensive1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingTreatmentBlood Pressure, High1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4RecruitingTreatmentHypertension,Essential1
4RecruitingTreatmentHypertensive2
4RecruitingTreatmentMetabolic Syndromes1
4RecruitingTreatmentNonalcoholic Fatty Liver Disease (NAFLD)1
4TerminatedTreatmentArterial Hypertension / Diabetes Mellitus Type 2 IRC or NIR1
4TerminatedTreatmentCoronary Arteriosclerosis / Hypertensive1
4TerminatedTreatmentHypertensive1
4Unknown StatusTreatmentAcute Coronary Syndromes (ACS) / Coronary Heart Disease (CHD) / Myocardial Infarction (MI)1
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentHypertensive2
Not AvailableCompletedNot AvailableArterial Hypertension1
Not AvailableCompletedNot AvailableHypertension,Essential1
Not AvailableCompletedNot AvailableHypertensive33
Not AvailableCompletedNot AvailableNeoplasms1
Not AvailableCompletedTreatmentHypertensive1
Not AvailableNot Yet RecruitingNot AvailableHypertensive1
Not AvailableRecruitingDiagnosticArterial Hypertension1
Not AvailableRecruitingTreatmentGraft Versus Host Disease (GVHD)1
Not AvailableRecruitingTreatmentPeripheral Artery Disease (PAD)1
Not AvailableTerminatedPreventionAcute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI) / Angina Pectoris / Hypertensive / Myocardial Ischemia1
Not AvailableUnknown StatusTreatmentDyslipidemias / Hypertensive / Insulin Resistance1
Not AvailableUnknown StatusTreatmentHypertensive1

Pharmacoeconomics

Manufacturers
  • Boehringer ingelheim
Packagers
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg/1
TabletOral80 mg/1
TabletOral40 mg
TabletOral80 mg
TabletOral20 mg/1
TabletOral
Tablet, multilayerOral
Prices
Unit descriptionCostUnit
Micardis 30 40 mg tablet Box110.11USD box
Micardis HCT 30 40-12.5 mg tablet Box106.34USD box
Micardis HCT 30 80-12.5 mg tablet Box106.18USD box
Micardis 30 80 mg tablet Box103.92USD box
Micardis HCT 30 80-25 mg tablet Box100.48USD box
Micardis 30 20 mg tablet Box99.7USD box
Micardis 20 mg tablet3.29USD tablet
Micardis hct 40-12.5 mg tablet3.29USD tablet
Micardis hct 80-12.5 mg tablet3.29USD tablet
Micardis hct 80-25 mg tablet3.29USD tablet
Micardis 40 mg tablet2.24USD tablet
Micardis 80 mg tablet2.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5591762No1994-01-072014-01-07Us
CA2060624No1999-12-212012-02-04Canada
US6358986No2000-01-102020-01-10Us
US7998953No2000-06-062020-06-06Us
US8003679No2002-10-062022-10-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)261-263 °CNot Available
water solubilityPractically insolubleNot Available
logP7.7Not Available
Caco2 permeability-4.82ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0035 mg/mLALOGPS
logP6.66ALOGPS
logP6.04ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)3.65ChemAxon
pKa (Strongest Basic)6.13ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area72.94 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity164.49 m3·mol-1ChemAxon
Polarizability58.61 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8794
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6061
P-glycoprotein inhibitor INon-inhibitor0.5261
P-glycoprotein inhibitor IIInhibitor0.8653
Renal organic cation transporterNon-inhibitor0.6047
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5255
CYP450 1A2 substrateInhibitor0.5699
CYP450 2C9 inhibitorNon-inhibitor0.5481
CYP450 2D6 inhibitorNon-inhibitor0.7796
CYP450 2C19 inhibitorNon-inhibitor0.5509
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.601
Ames testNon AMES toxic0.6432
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.8075 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9166
hERG inhibition (predictor II)Non-inhibitor0.7114
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03di-0000090000-219191b231632ae82938
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-03di-0002490000-d9a86d68a321494f4172
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-00li-0095500000-433f75bf696d30339ffe
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0093100000-d1a212009af2d2b6d576
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0093000000-dc77c406187bdc1b4750
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0000900000-2da316f976108d0ab57a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0000090000-fa13ab012f6c3edda644
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0fri-0094500000-fc4e746d5acf7c28974b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0093000000-739535a2fb80154ac329
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0093000000-7b45a183400fc2d5c56e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0079-0090000000-f2b72bb436b094188b4b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-03di-0000090000-4193d926fb43b7e7650a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00ri-0090400000-4c927fd317a9c571c8c1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0094000000-a362fb77a1bf330b4d4b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f79-0095000000-c9574b21fc223d1415ff
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-0d0b0eddab1ab829b1c1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-95cf0efe8a365f6e1b11
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0000900000-3c8f5cf8f5d9a897d72d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01p9-0093450000-1dd7fd500cf0b3c0dc32
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0000090000-d2b14455bf61ea4f82a1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0000090000-6187f6c1620a7c2b51b1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0000090000-dc95af971f11219cb750
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014j-0000690000-92f9c219585dd2f6abdd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002b-0091820000-b4160c5238973be1326b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0000900000-81da14e51168bd40dbc8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0000090000-e488353a2ab5a5ca95c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0000090000-45ac38d5e068041afc7f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0051930000-355f3efe4c799be31eee
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0091000000-0119ca397b44d63c12e1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0190000000-c8f628b5d1752b565720
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03fr-0290000000-e1a994dd22ac9af9bd71
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0000090000-79a32c207900b92a8001
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0000090000-522439ae25d7e43446e5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002b-0061930000-355af521f837490feefd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0091000000-28e6d3e6afd2cee22baf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0190000000-24d6dc729edb2e402cb5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03fr-0290000000-8ed1014ce3c441c09502
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0000900000-683d2b1a6727533bf2cc
MS/MS Spectrum - ESI-QTOF , positiveLC-MS/MSsplash10-014j-0000690000-e5484f50567b0ed1d402
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0011390000-909e49aea97bff3f66e6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0bt9-2596000000-b809729f5d533c915b79
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0020390000-96e1851c27d6f6e79183
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0bt9-0289000000-899a015c97aa18e79eb5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-06vi-3892000000-408ee10cb09fe63e849e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-016s-1493650000-7139ff8e100efd8f486c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016r-0081290000-363d23081a66306a3f9e

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Benzoic acids / Benzimidazoles / Benzoyl derivatives / N-substituted imidazoles / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Biphenyl / Benzimidazole / Benzoic acid or derivatives / Benzoic acid / Benzoyl / N-substituted imidazole / Imidazole / Azole / Heteroaromatic compound / Azacycle
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
biphenyls, benzimidazoles (CHEBI:9434)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Karlberg BE, Lins LE, Hermansson K: Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999 Feb;17(2):293-302. [PubMed:10067800]
  3. Balt JC, Mathy MJ, Nap A, Pfaffendorf M, van Zwieten PA: Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol. 2001 Jul;38(1):141-8. [PubMed:11444497]
  4. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T: AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther. 2001 Jul;298(1):62-70. [PubMed:11408526]
  5. Strohmenger HU, Lindner KH, Wienen W, Vogt J: Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. Resuscitation. 1997 Aug;35(1):61-8. [PubMed:9259062]
  6. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004 Oct 22;576(3):492-7. [PubMed:15498586]
  7. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501-29. [PubMed:11558835]
  8. McClellan KJ, Markham A: Telmisartan. Drugs. 1998 Dec;56(6):1039-44; discussion 1045-6. [PubMed:9878991]
  9. Galzerano D, Capogrosso C, Di Michele S, Galzerano A, Paparello P, Lama D, Gaudio C: New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010 Mar 24;6:113-33. [PubMed:20448797]
  10. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15. [PubMed:19147680]
  11. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21. [PubMed:16938288]
  12. Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. [PubMed:18580862]
  13. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8. [PubMed:15617852]
  14. Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9. [PubMed:17691961]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M: A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009 Feb;150(2):862-70. doi: 10.1210/en.2008-0502. Epub 2009 Jan 15. [PubMed:19147680]
  2. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K: Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006 Oct 1;72(1):184-90. Epub 2006 Jul 21. [PubMed:16938288]
  3. Kurtz TW: Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26. doi: 10.1038/ncpcardio0805. [PubMed:18580862]
  4. Yamagishi S, Takeuchi M: Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses. 2005;64(3):476-8. [PubMed:15617852]
  5. Kurtz TW: Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 Apr;42 Suppl 1:S9-16. [PubMed:15868121]
  6. Yamagishi S, Nakamura K, Matsui T: Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007 Aug;7(5):463-9. [PubMed:17691961]
  7. Yamagishi S, Takenaka K, Inoue H: Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Med Hypotheses. 2006;66(1):118-20. Epub 2005 Sep 12. [PubMed:16154710]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34